Simiso Sokhela to Female
This is a "connection" page, showing publications Simiso Sokhela has written about Female.
Connection Strength
0,355
-
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS. 2025 Mar 15; 39(4):448-456.
Score: 0,023
-
DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
Score: 0,023
-
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378.
Score: 0,023
-
The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa. BMC Public Health. 2024 Jul 16; 24(1):1900.
Score: 0,022
-
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. J Int AIDS Soc. 2024 Jul; 27(7):e26268.
Score: 0,022
-
Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426.
Score: 0,022
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
Score: 0,022
-
Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa. BMC Public Health. 2023 11 20; 23(1):2291.
Score: 0,021
-
Coronavirus Host Genomics Study: South Africa (COVIGen-SA). Glob Health Epidemiol Genom. 2022; 2022:7405349.
Score: 0,020
-
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022 03; 88(3):883-893.
Score: 0,019
-
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
Score: 0,019
-
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909.
Score: 0,019
-
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021 08 01; 35(10):1657-1665.
Score: 0,018
-
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
Score: 0,018
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
Score: 0,017
-
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
Score: 0,016
-
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437.
Score: 0,016
-
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. J Acquir Immune Defic Syndr. 2019 02 01; 80(2):224-233.
Score: 0,015